All phosphodiesterase type 5 inhibitors (PDE5I) have an FDA label indication for the treatment of erectile dysfunction (ED) and tadalafil has a label indication for the treatment of lower urinary tract symptoms (LUTS) in men. The intent of this document is to summarize the evidence on the safety and efficacy of the PDE5I for the treatment of benign prostatic hyperplasia (BPH) and LUTS, and in p...

PURPOSE The aim of this study was to evaluate the prevalence of lower urinary tract symptoms (LUTS) among Korean men aged ≥40 years. METHODS We performed a population-based, cross-sectional door-to-door survey on a geographically stratified random sample of men aged ≥40 years. All respondents were asked about the presence of individual LUTS using a questionnaire based on 2002 International Co...

BHP is theoretically the detection of prostatic hyperplasia, which is the benign proliferation of the stroma and epithelium, by histological study. However histological studies for all men are unfeasible in clinical practice, so BHP usually refers to the palpable enlargement of the prostate, which can be detected by clinical or ultrasonographic examination, or presence of urinary symptoms loose...

Lower urinary tract symptoms (LUTS) are a common complaint among aging men and are often caused by benign prostatic hyperplasia (BPH). A number of medical treatments for LUTS/BPH exist, such as alpha-blockers, 5alpha-reductase inhibitors, anticholinergics, phosphodiesterase type 5 (PDE5) inhibitors, and combination therapies. Agonist binding of the alpha(1A)-adrenergic receptor (AR), causing pr...

Benign prostatic hyperplasia (BPH) is a frequent cause of lower urinary symptoms, with a prevalence of 50% by the sixth decade of life. Hyperplasia of stromal and epithelial prostatic elements that surround the urethra cause lower urinary tract symptoms (LUTS), urinary tract infection and acute urinary retention. Medical treatments of symptomatic BPH include; 1) the 5alpha-reductase inhibitors,...

OBJECTIVE The aim of this study was to examine associations between diabetes and clinical markers of benign prostatic hyperplasia (BPH) in community-dwelling white and black men aged 40-79 years. RESEARCH DESIGN AND METHODS Data from the Olmsted County Study of Urinary Symptoms and Health Status and the Flint Men's Health Study were combined for a total study sample of 2,484 men. Severity of ...

materials and methods we retrospectively evaluated 150 consecutive transplant recipients at the university of jena 12 months postoperatively for the presence and treatment of luts related to bpo. results the mean age of the patients was 59 years (range 27 - 82 years). by 12 months postoperatively, 91% (n = 137/150) were off dialysis with a functioning kidney graft. two patients died during foll...

OBJECTIVE To examine the effect of questionnaire context on self-reported illness cognition. DESIGN A single-item measure of the perceived impact of lower urinary tract symptoms (LUTS) was embedded twice in a questionnaire battery completed by community-dwelling middle-aged males (N = 1,790). The impact measure was placed in two distinct questionnaire contexts; at the end of a general somatic...

10.2217/14750708.5.3.355 © 2 In the aging male, erectile dysfunction (ED) and lower urinary tract symptoms (LUTS) are common conditions that have been shown to be related. As life expectancy increases, treatments that target both ED and LUTS will prove increasingly valuable over the coming years. Phosphodiesterase type 5 (PDE5) inhibitors are used primarily to treat ED. Recently, studies have s...